EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Data on the Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease in Spain

Marta Araujo-Castro iD, Rogelio García-Centeno, Laura González, Felicia A Hanzu, Aida Orois iD, Rosa Camara, María Dolores Ollero García iD, Ana Irigaray Echarri, Paola Gracia Gimeno, Eider Pascual-Corrales iD, Betina Biagetti iD, Andrés Cardona und 19 weitere

Journal of Clinical Medicine · 25.10.2025 · 14 (21) · 7575

DOI: 10.3390/jcm14217575 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 25.10.2025. Verfasst von Marta Araujo-Castro und 30 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal & Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Colmenar Vi…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy and safety of osilodrostat in patients with Cushing’s disease (CD).

Methods

A retrospective, multicenter, real-world study of patients with CD. The main efficacy endpoint was the proportion of patients who were complete responders (urinary free cortisol [UFC] < the upper limit of normal and/or with adrenal insufficiency development).

Results

Thirty-seven CD patients were enrolled. There were 33 patients who initially received osilodrostat in monotherapy and 4 in combination. However, 3 patients of the monotherapy group were switched to combination therapy. The median duration of osilodrostat treatment was 5 months (range 1–93). All the patients were classified as responders: 33 (89.2%) had complete response and 4 partial response. A positive correlation was detected between the percentage of UFC decrease and the maximum (r = 0.481, p = 0.006) and the maintenance doses (r = 0.440, p = 0.011). The initial doses of osilodrostat were a predictor of complete response (vs. partial) (Odds ratio [OR] 2.82, p = 0.030). The median time to UFC normalization in the group of complete responders was 4 weeks (range 1–20) and UFC normalized before or at month 1 in 67% (n = 20/30) of the patients. Osilodrostat led to a significant decrease in systolic and diastolic blood pressure in parallel with a reduction of antihypertensive medications.

Conclusions

Osilodrostat leads to a complete UFC normalization in up to 90% of the patients with CD, in parallel with an improvement in the cardiometabolic profile. A proper titration of osilodrostat is important to achieve a complete response since a positive correlation between the doses and the UFC reduction was observed.

Schlagwörter

Stichwörter der Autor:innen

Cushing’s diseaseCushing’s syndromeosilodrostatpituitaryurinary free cortisol

Autor:innen und Institutionen

  • Endocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal & Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Colmenar Viejo Street km 9, 28034 Madrid, Spain.
  • Endocrinology & Nutrition Department, Hospital Universitario Gregorio Marañón, 28007 Madrid, Spain.
  • Endocrinology & Nutrition Department, Hospital Clinic de Barcelona, 08036 Barcelona, Spain.
  • Endocrinology & Nutrition Department, Hospital La Fe, 46600 Valencia, Spain.
  • Endocrinology & Nutrition Department, Hospital Universitario Navarra, 31008 Pamplona, Spain.
  • Endocrinology & Nutrition Department, Hospital Universitario Royo Villanova, 50015 Zaragoza, Spain.

ORCID-Profile: Marta Araujo-Castro, Aida Orois, María Dolores Ollero García, Eider Pascual-Corrales, Betina Biagetti, Rocío Villar-Taibo, Ignacio Bernabéu, Carmen Fajardo-Montañana, Cristina Novo-Rodríguez, Carmen Tenorio Jimenéz, Fernando Cordido, Lucía Manzano Valero, Miguel Paja Fano, Jessica Goi, Pablo Abellán, Pedro Iglesias, Alfonso Soto-Moreno

Zitieren

APA

Araujo-Castro, M., García-Centeno, R., González, L., Hanzu, F. A., Orois, A., Camara, R., García, M. D. O., Echarri, A. I., Gracia Gimeno, P., Pascual-Corrales, E., Biagetti, B., Cardona, A., González Molero, I., Simo-Servat, A., Guerrero Pérez, F., Villar-Taibo, R., Bernabéu, I., Fajardo-Montañana, C., Novo-Rodríguez, C., …, & Soto-Moreno, A. (2025). Real-World Data on the Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease in Spain. Journal of Clinical Medicine, 14(21), 7575. https://doi.org/10.3390/jcm14217575

Vancouver

Araujo-Castro M, García-Centeno R, González L, Hanzu FA, Orois A, Camara R, et al. Real-World Data on the Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease in Spain. Journal of Clinical Medicine. 2025;14(21):7575. doi:10.3390/jcm14217575

BibTeX
@article{AraujoCastro2025,
  author = {Araujo-Castro, Marta and García-Centeno, Rogelio and González, Laura and Hanzu, Felicia A and Orois, Aida and Camara, Rosa and García, María Dolores Ollero and Echarri, Ana Irigaray and Gracia Gimeno, Paola and Pascual-Corrales, Eider and Biagetti, Betina and Cardona, Andrés and González Molero, Inmaculada and Simo-Servat, Andreu and Guerrero Pérez, Fernando and Villar-Taibo, Rocío and Bernabéu, Ignacio and Fajardo-Montañana, Carmen and Novo-Rodríguez, Cristina and Tenorio Jimenéz, Carmen and Calatayud, María and Moure Rodríguez, María Dolores and Cordido, Fernando and Castro, Ana and Valero, Lucía Manzano and Paja Fano, Miguel and Goi, Jessica and Aulinas, Anna and Abellán, Pablo and Iglesias, Pedro and Soto-Moreno, Alfonso},
  title = {Real-World Data on the Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease in Spain},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {21},
  pages = {7575},
  doi = {10.3390/jcm14217575}
}
Kostenlos starten →